Ex vivo lung perfusion (EVLP) promises to be a comprehensive platform for assessment, reconditioning, and preservation of donor lungs and has been dramatically changing the face of clinical lung transplantation. Besides its increasing role in lung transplantation, EVLP has also been recognized as a useful tool for translational research involving the lungs. Based on recent remarkable evidence and experience using EVLP in lung transplantation, there is growing interest in, and expectations for, the use of EVLP beyond the field of lung transplantation. By combining EVLP with advances in regenerative medicine, stem cell biology, and oncology, the evolving technology of EVLP has tremendous potential to advance pulmonary medicine and science. In this review, we revisit recent advances in EVLP technology and research and discuss the future translation of EVLP applications into life-changing medicine.
Ex vivo lung perfusion (EVLP) has recently offered an alternative to conventional approaches for donor lung assessment, reconditioning, and preservation and breathes new life into clinical lung transplantation. 1 EVLP itself is not a new
concept. An ex vivo isolated lung perfusion technique was prevalent in the 1950s for application of chemotherapeutic agents. 2 In 1970, Jirsch et al 3 introduced EVLP as a method to assess the quality of lung grafts during storage prior to transplantation using a canine model. In 2001, three decades after Jirsch et al's report, Dr Stig Steen from Lund, Sweden reintroduced EVLP techniques to the field of clinical lung transplantation and reported the first successful case using EVLP in a lung graft from a non-heart-beating donor. 4 Cypel et al 5 in Toronto, Canada modified Dr Steen's EVLP techniques, started the first clinical trial of EVLP, and reported excellent outcomes in 2011; this study had a major impact on the lung transplantation community.
EVLP is a game-changing tool to select lungs suitable for transplantation when evaluating lungs of "marginal" quality or from donors with "extended" criteria. The great utility of EVLP has been well illustrated by many case series. [5] [6] [7] [8] Consequently, EVLP has contributed to an increase in transplantable lungs of at least 15% to 20% despite a limited donor pool. 9, 10 Lungs donated after circulatory death (DCD) (also called nonheart-beating donor) are often the most difficult "marginal" donor lungs to assess, and EVLP appears to have a particularly high value in selecting safely transplantable DCD lungs. In most reports, the incidence of primary graft dysfunction (PGD) after EVLP and transplantation has been similar to or slightly higher than the incidence after conventional lung transplantation without EVLP. 11, 12 However, for DCD lungs, early outcomes after transplantation, including the incidence of severe PGD, remain concerning. 13 Lung suitability for transplantation after EVLP is currently determined primarily by physiological parameters assessed during EVLP. Further investigation is needed to reduce PGD after EVLP, such as identifying biomarkers that predict the development of PGD or treating lung injuries that may promote PGD prior to transplantation. 14, 15 The recent success of EVLP in clinical lung transplantation is also contributing significantly to advances in translational research in the lungs. The advances and potential of EVLP in translational research are not restricted to transplantation and include advances in pulmonology, oncology, and thoracic surgery. EVLP attempts to simulate the in vivo environment of the lungs using ventilation and perfusion and thereby allows researchers to assess unique characteristics of the lungs, including alveolar metabolism and microcirculation as well as the reaction of the lungs to therapies and interventions. Of note, there is increasing availability of human lungs that can be used for research, and by making the best use of these opportunities, human lungs on EVLP can play a pivotal role in top-notch lung translational research. In this review, we revisit advances in research using EVLP technology and discuss the future translation of EVLP applications into life-changing medicine.
Revisiting the Technology

Standard Techniques for EVLP in Lung Transplantation
A typical EVLP circuit is shown in Figure 1A . The EVLP system has two primary components: (1) a circuit that circulates, deoxygenates, and filters the perfusate that is circulated through the lung vasculature and (2) a ventilator that provides oxygenation to the lungs through the bronchi. The perfusate drained from the left atrium (pulmonary venous return) is deoxygenated through a gas exchange membrane, which allows the maintenance of normal venous oxygen levels before entering the lungs (Fig 1B) . The prevailing perfusate is a lung-specific perfusion solution with optimal osmolarity and high dextran content, which is designed to coat the endothelium and protect it from excessive leukocyte interaction as well as other injuries (Steen solution, XVIVO Perfusion). Various physiological parameters in the lung grafts, such as perfusion flow rate, pulmonary vascular resistance, and lung compliance, are continuously monitored during EVLP. Perfusate gas levels, which are equivalent to arterial blood gases in vivo, are routinely used to evaluate the function and quality of the lung grafts. In addition, glucose and lactate levels in the perfusate can be monitored to evaluate the metabolic profiles of the lung grafts. 7, 16 Indeed, the deoxygenator is only present to allow physiological assessment of gas exchange. In other words, if an alternative, such as robust biomarkers for lung injuries that can stratify donor lungs during EVLP, is available, there might be no need for deoxygenation of the perfusate.
Both bronchoscopy and radiographic assessments, such as chest radiography and CT imaging, can be implemented during EVLP (Fig 1C) . Thus, normothermic EVLP allows the evaluation of lung grafts by multiple criteria under conditions that mimic in vivo pulmonary physiological conditions. The relationship between the parameters monitored during EVLP and transplantation outcomes, such as the incidence of PGD, is a current important area of investigation.
Currently, there are three major EVLP protocols with different underlying rationales: the Lund protocol, the Toronto protocol, and a portable EVLP protocol (the OCS [Organ Care System; TransMedics, Andover, MA] protocol). The differences in their settings and characteristics are attributed to their aim and strategy using EVLP, which are indeed worth discussing to deepen the insights into pulmonary physiology. Further evidence is needed to prove which protocol is superior regarding each major role of EVLP, that is, lung assessment, reconditioning, and lung preservation.
It is also essential to recognize both the advantages and disadvantages inherent to the EVLP technology ( Fig 1A) . Accumulating evidence supports the benefits of EVLP, the greatest of which is the opportunity for reconditioning and improving the quality of lung grafts prior to transplantation. Extending preservation time without compromising outcomes is another significant benefit. 17, 18 However, despite its promise, EVLP is not a "magic bullet." Some lung grafts exhibit substantial inflammation on EVLP despite reasonable graft function. 19, 20 Lung grafts on EVLP are also journal.publications.chestnet.org exposed to airway hypoxia, possibly due to a compromised blood supply after disruption of the in vivo bronchial artery circulation, leading to loss of integrity of the microvasculature and compromised cellular metabolism with high glucose consumption. 21, 22 Moreover, using continuous ventilation in the setting of EVLP can cause ventilatorinduced lung injury. 23 We must be mindful of these caveats moving forward with translational medicine and research using EVLP.
• 
Translational Research Using EVLP
Appropriate Translation from Bench to Bedside
The "living" lungs maintained with perfusion and ventilation on EVLP provide valuable opportunities for science, allowing many types of research projects, which have included pharmacotherapy, stem-cell therapy, gene therapy, and organ/tissue engineering. Results obtained using lungs on EVLP should be highly translatable to clinical practice. Although most of the landmark work using EVLP has been done on lungs from humans or from large animals (such as pigs), 24 EVLP on lungs from rodents has also been reported and is reproducible. 25 To translate the evidence obtained from rodent EVLP models into clinical practice, however, some limitations must always be borne in mind. First, there are multiple differences between human and rodent EVLP, including a lower perfusion flow in the rat EVLP model. 25 Second, almost all strains of rat are hypersensitive to dextran. When we translate the data obtained in rat models to clinical trials, we must be mindful that direct histamine release in reaction to dextran occurs only in rats. 26 By recognizing the limitations of rodent models and optimizing the available opportunities for research using human lungs, EVLP using small animal, large animal, and human models will be a powerful system to advance translational science in lung transplantation, pulmonology, oncology, and thoracic surgery.
Revisiting Pulmonary Mechanics and Unique Characteristics of the Lungs
The lung exists for gas exchange, that is, the transfer of oxygen from the air to the blood and CO 2 from the blood to the air. To enable gas exchange, however, perfusion and ventilation must be synchronized in close proximity at an appropriate temperature-the physiology of the lung is recognized through EVLP, which "revitalizes" the organ from a static state. Using a rodent EVLP model system, we recently demonstrated that lungs on EVLP exhibit fundamental tissue hypoxia because of single perfusion (through the pulmonary arteries only) in lungs that are normally perfused with dual circulation (through both the bronchial and pulmonary arteries). When we preserved rodent lung grafts on EVLP by perfusing both the bronchial and pulmonary arteries (dual perfusion), posttransplantation outcomes improved. 22 Because this dual-perfusion concept takes the pulmonary anatomy and physiology in vivo into account, the technique shows promise of improving outcomes in a clinical setting.
The lungs are also uniquely characterized by lower metabolic requirements and a higher tolerance of ischemia and hypoxia than other solid organs such as heart, liver, and kidney. [27] [28] [29] With these characteristics and the basics in pulmonary mechanics borne in mind, EVLP itself could be a good platform to revisit the study of basic lung physiology (such as the interaction of vascular pressures and ventilation and barrier protection), promoting the development of new treatment strategies for lung diseases.
EVLP Using Human Lungs
Human lungs are valuable resources for translational research, in particular for studying challenging lung diseases. 30 Because of dedicated efforts by organ procurement organizations, lungs that have been declined for transplantation are commonly available in the United States for research purposes (Fig 2) . 31 This is not the case in some other countries due to ethical barriers. Because human lungs are available, the physiology and biology of advanced lung diseases, such as idiopathic pulmonary arterial hypertension, scleroderma, and pulmonary emphysema, can be studied using EVLP. It is also possible to test new experimental drugs or therapies for advanced lung diseases, providing more accurate information to inform subsequent larger clinical trials.
EVLP can also be performed using lungs obtained from cadavers after a rapid or "warm" autopsy, providing an additional source of human lungs for translational research. 32 The short interval (within 6 h) between patient death and the start of the autopsy allows the collection of fresh tissues and circumvents many issues related to postmortem degradation. We have accrued four successful cases of EVLP using warm-autopsied lungs with idiopathic pulmonary fibrosis. Gas exchange capacity, pulmonary vascular resistance, pulmonary compliance, and organ/cellular metabolism were successfully evaluated in real time on EVLP. Moreover, lung biopsy, BAL, and perfusate samples were collected for cellular, molecular, proteomic, and genomic analyses. Further refinement or modification of EVLP techniques may be needed for warm-autopsied lungs given their complexity compared with human donor lungs that are unsuitable for transplantation. For example, the lungs are not perfused and ventilated during the postmortem period, so clots in the perfusate and secretions and fluid in the airways may affect the cellular viability of the lungs.
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EVLP as a Therapeutic Platform for Reconditioning or Treating Injured Lungs
EVLP promises to be a useful platform to recondition or treat injured lungs prior to lung transplantation. Several therapeutic approaches are currently under investigation, and promising advances have been made using drug therapy, gene therapy, stem cell therapy, and medical gas therapy. 37 Further studies are needed to better control tissue absorption of drugs administered during EVLP to avoid injuries due to toxic concentrations of the drugs in the lungs. However, if these issues are resolved, drug therapy administered during EVLP may be an ideal method to target therapy and avoid systemic side effects of the drugs on other organs.
Gene therapy: Similar to drug therapy, gene therapy administered during EVLP is also a feasible targeted approach to recondition the lungs. A pilot study of interleukin-10 gene transfection using adenovirus infection during EVLP was reported with notable success and improved posttransplantation outcomes. 38 This was an encouraging study that foreshadows the potential major impact of gene therapy during EVLP. We must be mindful of viral toxicity, however, as adenoviral vectors can induce inflammation. 39 Nonviral gene delivery methods (such as electroporation, sonoporation, and magnetofection) during EVLP may be valuable alternatives.
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Excellent Good Marginal Poor Bad
Graft Quality
• Only 15%-20% of total donors for transplantation.
• PGD and CLAD are concerns for recipient survival.
Transplantable lungs
• Lung quality is assessed on EVLP.
• 60%-80% of marginal lungs can be transplantable by reconditioning on EVLP.
Marginal Lungs including DCD and DBD
Use for experimental EVLP for lung research including Stem cell therapy: Because of a number of evolving technologies, there have been rapid advances in stem cell therapy over the past few years, and stem cell therapy has become a potential clinical reality for complicated lung diseases. 43 In the field of lung transplantation, mesenchymal stem cells (MSCs) have been well investigated because they have multipotent capacities and can secrete paracrine factors that regulate endothelial and epithelial permeability, attenuate inflammation, and regulate immunoreaction in lungs. 44, 45 These beneficial effects of MSCs have been confirmed in lungs on EVLP with various types of acute lung injury. In Escherichia coli-injured human lungs, tracheal instillation of MSCs during EVLP restored alveolar fluid clearance, reduced inflammation, and exerted antimicrobial activity, in part through keratinocyte growth factor. 46 The Toronto group also reported that intravascular administration of MSCs in pig lungs on EVLP led to decreases in circulating interleukin-8 levels, suggesting potential therapeutic effects against ischemia-reperfusion injury and PGD. 47 Multipotent adult progenitor cells are another promising resource for stem cell therapy and have shown remarkable anti-inflammatory effects in lungs on EVLP. 48 Although the lung grafts used in studies of stem cell therapies during EVLP exhibited major lung injuries attributed to both inflammation and tissue hypoxia and ischemia, the role of stem cell therapy in recovery from these injuries appeared to be restricted to paracrine signaling from the cells that promoted the cellular recovery process. 49 Stem cell therapy also has the potential to replace damaged cells with new cells differentiated from the stem cells. 50 Further investigation is needed to integrate this stem cell functionality with EVLP use. If accomplished, integrity and function in lung grafts could be improved significantly.
Medical gas therapy: Such therapy through the ventilator circuit during EVLP is another promising approach to recondition or treat injured lungs. 51 We have explored the therapeutic properties of hydrogen and reported that preconditioning the lungs with inhaled hydrogen on EVLP attenuated proinflammatory changes and reinforced mitochondrial biogenesis, leading to improved graft function after lung transplantation. 52 . At the specialized center, the lungs will be reconditioned on EVLP and then shipped to transplantation centers. By reducing errors and addressing other technical concerns, this centralization should increase the number of successfully reconditioned transplantable lungs. More importantly, the success of this trial will have a major impact and may yield a successful structural model to optimize limited donor resources. 61 Centralization of lungs on EVLP could also help move translational science in the lungs forward. For instance, centralizing the supply of human lungs with advanced lung diseases or specific lung pathologic conditions obtained through all available processes (donation after being declined for transplantation, warm autopsy, and so on) at a specialized center may encourage collaboration and expedite therapeutic discoveries. The physiological and biological characteristics of these lungs could be continuously monitored and assessed on EVLP with or without treatment, and all the data could be shared in real time through cloud-based video conferencing nationwide to specialists in working groups. Specialized centers could also be used as training facilities for beginners to learn the EVLP techniques and ultimately launch new EVLP programs at their institutions. In addition, centralization could reduce the financial burden of conducting EVLP projects, some of which require expensive special solutions or many refined disposables.
Conclusions: The "Ideal" EVLP Lungs maintained on the current standard EVLP protocols are not completely equivalent to lungs in vivo.
It is exciting to discuss potential research projects using EVLP given its potent capabilities as described in this review; however, it is even more important to continue to evolve the technology toward an "ideal" EVLP that completely simulates in vivo lungs. 21, 22 This evolution will both require and promote top-notch translational research, and the establishment of such an ideal EVLP can accelerate the translation of science in the lungs into life-changing chest medicine. Therefore, translational research using EVLP will continue to evolve and contribute to clinical practice and science.
